Latest news with #Miracell
Korea Herald
25-07-2025
- Business
- Korea Herald
Miracell launches Korea's first generative AI voice system for hospitals
Korean stem cell research company Miracell has introduced the nation's first generative AI-powered voice consultation system designed for medical institutions. Co-developed with Europe-based Vee, a Warsaw-listed AI company, the solution marks a major shift in healthcare automation. The company said Monday it has secured exclusive distribution rights for Vee's AI solution across Asia and is working closely with Vee Korea to customize the system for local hospitals. Unlike traditional rule-based ARS systems, the new AI tool uses natural language processing to deliver 24-hour conversational support, handling appointment scheduling, billing inquiries, patient reminders and general questions. The system is particularly effective during nights and weekends, when staffing is limited. It integrates with hospital customer relationship management systems and supports both inbound and outbound calls. Hospitals can trial the solution free for one month, lowering the adoption barrier. 'Generative AI can dramatically improve service quality in medical care,' said Shin Hyun-soon, CEO of Miracell. 'This isn't just an upgrade — it's a survival strategy for the health care sector.' Vee provides the underlying large language model engine, customized for Korean language and clinical context. A future version will link with Miracell's Celldoc platform, integrating patient consultations, appointments, and treatment records into a single interface. By combining its stem cell expertise with cutting-edge AI, Miracell aims to set a new standard in the health care industry. 'We're starting with clinics already using Smart-MCell,' a Miracell spokesperson said. 'But this is just the beginning. With AI, we hope to bring patients and caregivers even closer, and open the door to a more responsive, intelligent health care experience.'
Korea Herald
30-04-2025
- Business
- Korea Herald
Miracell enters Dubai to boost biotech presence in Middle East
Miracell, a Korean biotech company, unveiled its plans to expand into the stem cell biohealth market in Dubai of the United Arab Emirates on Wednesday, as part of efforts to strengthen its presence in the Gulf Cooperation Council region. Dubai has become a key center for the medical and biohealth industries in the Middle East, driven by both rising demand for healthcare services and interest in technological innovation. Miracell aims to develop stem cell therapies for various diseases, providing patients with alternative treatment options in the field of regenerative medicine. The company is also seeking to collaborate with local medical institutions and research organizations. These partnerships are expected to support joint research, enable technology transfer and lower market entry barriers. In addition, Miracell intends to hold seminars and workshops aimed at health care professionals and the public to increase understanding of stem cell technologies. The company's move into the Dubai market reflects its broader strategy to expand internationally while contributing to the development of regenerative medicine in the GCC region. By entering the Middle East, Miracell aims to build credibility and explore new avenues for growth.
